Posts by Rachel S. Knipe, MD
-
Targeted Nanoparticles Permit Cell-specific Drug Delivery in Pulmonary Fibrosis
Massachusetts General Hospital researchers developed nanoparticles that target myofibroblasts in fibrotic lung tissue, using a peptide recognized by the angiotensin II type 2 receptor. Inhibiting the Rho/MRTF/SRF pathway was therapeutic in a mouse model of pulmonary fibrosis, with minimal off-target toxicity.
-
New Target Identified for Treatment of Pulmonary Fibrosis
Rachel S. Knipe, MD, Benjamin D. Medoff, MD, and colleagues have shown in an animal model that an endothelial cell surface receptor, S1PR1, modulates the fibrotic response to lung injury. Agonism of its expression or function may be a novel and effective antifibrotic approach.
-
Endothelial Signaling Pathway Linked to Pulmonary Fibrosis
Research at Massachusetts General Hospital identifies a link between endothelial S1PR1 and the development of pulmonary fibrosis.
-
ARDS Related to COVID-19 Expected to Cause Increase of Pulmonary Fibrosis
Within the next year, physicians can expect to see increased numbers of patients with fibrotic lung disease that has developed as a complication of acute respiratory distress syndrome related to COVID-19.
-
Will COVID-19 cause more IPF?
Many people are saying ... with high rates of COVID-19 ARDS, we will be seeing more pulmonary fibrosis in the coming years.
Pulmonary and Critical Care Medicine
The Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital provides comprehensive care for the full range of respiratory conditions and diseases.